This clinical trial is focused on studying the long-term safety and effectiveness of a medication called baricitinib in treating a condition known as Juvenile Idiopathic Arthritis (JIA). JIA is a type of arthritis that affects children, causing joint pain and inflammation. The study involves participants aged 1 to less than 18 years who have previously been treated with baricitinib for JIA.

The purpose of the study is to determine if baricitinib is safe and effective for children with JIA. Participants will receive the medication in the form of a tablet or oral suspension, which means it is taken by mouth. The study will monitor the participants over a period to observe any side effects and to see how well the medication works in managing the symptoms of JIA.

Throughout the study, some participants may receive a placebo, which is a substance with no active medication, to compare the effects of baricitinib. The study aims to gather information on the number of participants who experience serious side effects or need to stop taking the medication permanently. This information will help in understanding the long-term use of baricitinib in treating JIA in children.